Different dosages of vonoprazan for gastroesophageal reflux disease: study protocol for a pragmatic, crossover-cluster, randomized controlled trial with patient preference arms

BACKGROUND: Vonoprazan results in more potent acid suppression for gastroesophageal reflux disease (GERD) than proton pump inhibitors. It has only been approved for treating erosive esophagitis in China, but 30–40% of GERD patients cannot achieve the goal of treatment with vonoprazan 20 mg daily. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Dongke, Zhou, Dan, Liu, Xinghuang, Xu, Zhiyue, Bai, Tao, Hou, Xiaohua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691065/
https://www.ncbi.nlm.nih.gov/pubmed/38041136
http://dx.doi.org/10.1186/s13063-023-07760-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691065/
https://www.ncbi.nlm.nih.gov/pubmed/38041136
http://dx.doi.org/10.1186/s13063-023-07760-9

Ejemplares similares